Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
56.72M | 55.64M | 52.55M | 45.56M | 48.30M | 41.98M | Gross Profit |
33.64M | 33.11M | 29.46M | 21.35M | 27.71M | 25.42M | EBIT |
-14.00M | -13.64M | -22.84M | -40.55M | -24.07M | -15.19M | EBITDA |
-12.16M | -11.14M | -19.15M | -43.11M | -23.10M | -13.65M | Net Income Common Stockholders |
-15.51M | -15.12M | -23.69M | -47.39M | -26.85M | -16.69M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
11.19M | 22.04M | 36.49M | 62.39M | 99.44M | 57.45M | Total Assets |
40.29M | 44.69M | 56.94M | 86.22M | 123.44M | 78.38M | Total Debt |
5.03M | 23.00M | 23.72M | 34.50M | 27.48M | 26.66M | Net Debt |
-6.16M | 969.00K | -12.77M | -27.89M | -71.96M | -30.79M | Total Liabilities |
33.89M | 35.15M | 34.25M | 43.76M | 38.51M | 36.54M | Stockholders Equity |
6.40M | 9.54M | 22.69M | 42.46M | 84.94M | 41.84M |
Cash Flow | Free Cash Flow | ||||
-15.45M | -13.79M | -15.29M | -36.46M | -22.64M | -14.54M | Operating Cash Flow |
-14.91M | -13.28M | -14.46M | -32.14M | -20.27M | -14.08M | Investing Cash Flow |
-536.00K | -515.00K | -804.00K | -4.32M | -2.42M | -455.00K | Financing Cash Flow |
-627.00K | -663.00K | -10.63M | -489.00K | 64.68M | -97.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $138.34M | ― | -117.50% | ― | 1.78% | 22.46% | |
55 Neutral | $106.91M | ― | -1552.23% | ― | 25.46% | 21.83% | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
52 Neutral | $50.58M | ― | 138.92% | ― | 64.15% | 41.65% | |
46 Neutral | $39.69M | ― | -1454.41% | ― | 35.76% | 47.48% | |
43 Neutral | $79.87M | ― | -41.36% | ― | -44.17% | 12.77% | |
39 Underperform | $29.27M | ― | -51.22% | ― | -5.72% | 48.12% |
On May 9, 2025, Exagen Inc. successfully closed its public offering of 3,350,000 shares of common stock at $5.25 per share, raising approximately $18.6 million in net proceeds. The offering, which included the full exercise of the underwriter’s option to purchase an additional 502,500 shares, resulted in gross proceeds of about $20.2 million, enhancing Exagen’s financial position and potentially strengthening its market presence in the autoimmune diagnostics industry.
On May 8, 2025, Exagen Inc. entered into an underwriting agreement with Canaccord Genuity LLC for the issuance and sale of 3,350,000 shares of its common stock at $5.25 per share. The offering, expected to close on May 9, 2025, aims to raise approximately $16.2 million in net proceeds, which will be used for working capital and potential acquisitions. This move is part of Exagen’s strategy to enhance its financial position and explore growth opportunities in the autoimmune diagnostics market.
On April 25, 2025, Exagen Inc. entered into a Credit Agreement with Perceptive Credit Holdings IV, LP, securing a senior secured delayed draw term loan facility of up to $75 million, with an initial $25 million tranche funded to refinance existing debt and extend the maturity. This strategic financial move is aimed at strengthening Exagen’s balance sheet and providing growth capital, allowing the company to further its leadership in autoimmune testing solutions and enhance patient care. The agreement includes additional tranches contingent on revenue and business development milestones, with the loan secured by Exagen’s assets and accompanied by a warrant to purchase shares of Exagen’s common stock.